Intrapersonal and populational heterogeneity of the chemokine RANTES.
BACKGROUND
Current immunoassays for the chemokine RANTES (regulated on activation, normal T-cell expressed and secreted) are not tailored for specific isoforms that exist endogenously, despite the fact that variants with modified activity are known to exist. This is surprising in view of this protein's ubiquitous increased presence in many diseases and that the 2 established isoforms are truncated by enzymes also correlated to disease. An in-depth population survey of RANTES heterogeneity in the context of multiple diseases via a mass spectrometric immunoassay (MSIA) may resolve this issue.


METHODS
We developed an MSIA for RANTES and endogenous variants apparent in human plasma. Samples from multiple cohorts of individuals (type 2 diabetes, congestive heart failure, history of myocardial infarction, and cancer patients) were run in parallel with samples from healthy individuals (239 people total). We used 230 microL of plasma per individual and tabulated relative percent abundance (RPA) values for identified isoforms.


RESULTS
We detected at least 19 variants, including the dipeptidyl peptidase IV (DPP-IV)-truncated variant. The majority of variants were unreported in the literature. Identifiable modifications included N- and/or C-terminal truncations, oxidation, glycation, and glycosylation. We observed statistically significant differences in RPA values for multiple variants between disease cohorts and recognized prospective disease-specific protein profiles for RANTES.


CONCLUSIONS
Because of widespread interest in the clinical value of RANTES, the protein diversity established here may aid in the design of future, fully quantitative assays. Equally important, an inclusive qualitative understanding of RANTES heterogeneity may present new insights into the relationship between RANTES and disease.
Oran
Paul E
PE
Molecular Biomarkers, The Biodesign Institute at Arizona State University, Tempe, AZ 85287, USA.
Sherma
Nisha D
ND
Borges
Chad R
CR
Jarvis
Jason W
JW
Nelson
Randall W
RW
D018946:Chemokine CCL5 / Q000097:blood*; D005260:Female; D006031:Glycosylation; D006801:Humans; D007118:Immunoassay; D008297:Male; D013058:Mass Spectrometry
D018946:Chemokine CCL5
Atherosclerosis. 2007 Jul;193(1):142-50
16842799
Clin Chem. 2010 Feb;56(2):281-90
20022981
J Immunol. 1988 Aug 1;141(3):1018-25
2456327
Arch Dermatol Res. 2001 Jul;293(7):350-5
11550808
J Immunol. 1998 Apr 15;160(8):4034-41
9558113
J Exp Med. 1997 Dec 1;186(11):1865-72
9382885
Clin Cancer Res. 2001 Feb;7(2):285-9
11234881
Clin Chem. 2006 Jun;52(6):1181-9
16613997
J Biol Chem. 1998 Mar 27;273(13):7222-7
9516414
J Leukoc Biol. 2006 Dec;80(6):1395-404
16963625
J Am Soc Nephrol. 2000 Jan;11(1):152-176
10616852
J Lipid Res. 2003 Mar;44(3):630-9
12562854
Immunity. 2001 Apr;14(4):377-86
11336683
Pharmacol Rev. 2000 Mar;52(1):145-76
10699158
Nat Clin Pract Nephrol. 2007 Mar;3(3):164-70
17322928
Diabetes. 2005 Dec;54 Suppl 2:S11-7
16306328
Kidney Int Suppl. 2006 Jul;(102):S29-33
16810307
Cancer Res. 2002 Feb 15;62(4):1093-102
11861388
J Exp Med. 1992 Aug 1;176(2):587-92
1380064
Clin Chem. 2010 Feb;56(2):202-11
19926773
Kidney Int. 2005 Sep;68(3):998-1007
16105030
Annu Rev Immunol. 2000;18:217-42
10837058
Mol Cell Proteomics. 2007 Jul;6(7):1183-7
17468123